WHO Collaborating Centre for Reference and Research on Influenza, North Melbourne, VIC, Australia. aeron.hurt@infl uenzacentre.org
Lancet Infect Dis. 2012 Mar;12(3):240-8. doi: 10.1016/S1473-3099(11)70318-8. Epub 2011 Dec 18.
Influenza A H1N1 2009 virus caused the first pandemic in an era when neuraminidase inhibitor antiviral drugs were available in many countries. The experiences of detecting and responding to resistance during the pandemic provided important lessons for public health, laboratory testing, and clinical management. We propose recommendations for antiviral susceptibility testing, reporting results, and management of patients infected with 2009 pandemic influenza A H1N1. Sustained global monitoring for antiviral resistance among circulating influenza viruses is crucial to inform public health and clinical recommendations for antiviral use, especially since community spread of oseltamivir-resistant A H1N1 2009 virus remains a concern. Further studies are needed to better understand influenza management in specific patient groups, such as severely immunocompromised hosts, including optimisation of antiviral treatment, rapid sample testing, and timely reporting of susceptibility results.
2009 年甲型 H1N1 流感病毒引发了一个时代的首次大流行，当时许多国家都有神经氨酸酶抑制剂抗病毒药物。在大流行期间检测和应对耐药性的经验为公共卫生、实验室检测和临床管理提供了重要的经验教训。我们提出了针对 2009 年大流行流感 A（H1N1）病毒感染患者的抗病毒药物敏感性检测、结果报告和管理的建议。持续对流行流感病毒的抗病毒耐药性进行全球监测对于为抗病毒药物的使用提供公共卫生和临床建议至关重要，特别是因为社区传播的奥司他韦耐药性 A（H1N1）2009 病毒仍然令人担忧。需要进一步研究以更好地了解特定患者群体（如严重免疫功能低下宿主）的流感管理，包括优化抗病毒治疗、快速样本检测和及时报告药物敏感性结果。
